SCHEMBL13656113

SCHEMBL13656113

COOSNc1ccc(CCC(=O)N2CCN(c3ccc(F)c(F)c3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.49
GRIN2B Q13224 1/20 0.49
GFER P55789 1/20 0.47
ADAMTS5 Q9UNA0 2/20 0.46
MMP2 P08253 1/20 0.46
ME2 P23368 2/20 0.46
ME1 P48163 2/20 0.46
ME3 Q16798 2/20 0.46
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
LMNA P02545 4/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
CYP2D6 P10635 2/20 0.42
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
SSTR1 P30872 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13656110 0.86 GRIN1 (0.67) GRIN1GRIN2BADAMTS5MMP2ME2
SCHEMBL13656236 0.85 MAPT (0.53) GRIN1GRIN2BME2ME1ME3
SCHEMBL12575488 0.84 GRIN1 (0.56) GRIN1GRIN2BGFERADAMTS5MMP2
SCHEMBL2017472 0.80 GRIN1 (0.74) GRIN1GRIN2BGFERADAMTS5MMP2
SCHEMBL3799394 0.78 GFER (0.74) GFERADAMTS5MMP2ME2ME1
SCHEMBL13656118 0.72 GRIN1 (0.69) GRIN1GRIN2BALDH1A1SMN1; SMN2LMNA
SCHEMBL2292606 0.71 KMT2A (0.66) GFERALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL3796885 0.71 GFER (0.67) GFERME2ME1ME3ALDH1A1
SCHEMBL12575993 0.70 GRIN1 (0.57) GRIN1GRIN2BME2ME1ME3
SCHEMBL21582753 0.69 ADAMTS5 (0.52) GFERADAMTS5MMP2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 GRIN1 1/4885GRIN2B 7/4885GFER 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.